UBS Downgrades BAT Rating to "Neutral" in Recent Report

BAT by 2FIRSTS.ai
Jan.24.2024
UBS Downgrades BAT Rating to "Neutral" in Recent Report
UBS downgrades BAT's rating from "buy" to "neutral" and lowers target price from 2900p to 2400p due to doubts regarding revenue targets.

German news agency dpa-AFX Analyzer reported on January 22nd that UBS has recently downgraded its rating on British American Tobacco (BAT) from "buy" to "neutral", while also lowering the stock price target from 2900 pence to 2400 pence.

 

In the latest research report, analyst Faham Baig from the bank mentioned that British American Tobacco has adopted multiple strategies to address the gradual transformation in the tobacco industry, and to some extent, these strategies have been successful. However, he noted that the company's performance has been inconsistent in executing these strategies. He expressed doubt about the company's revenue target set for 2025 in the "new business areas," believing that it may be challenging to achieve.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK vape retailer VPZ to expand manufacturing, open 40 stores in 2026
UK vape retailer VPZ to expand manufacturing, open 40 stores in 2026
UK specialist vape retailer VPZ has launched a multi-million-pound investment programme to boost domestic production capacity and tighten supply-chain controls. The plan includes adding a fifth production line, opening 40 new stores across the UK in 2026 and creating hundreds of jobs, while establishing a bonded warehouse at its Edinburgh headquarters as regulation tightens and a vaping tax is planned.
Feb.02 by 2FIRSTS.ai
France drops a vaping clause from the 2026 finance bill after use of Article 49.3
France drops a vaping clause from the 2026 finance bill after use of Article 49.3
A provision in France’s 2026 finance bill intended to regulate vaping products was abandoned after Sébastien Lecornu used Article 49.3 on January 20 to commit the government’s responsibility on the “revenue” section of the state budget.
Jan.21 by 2FIRSTS.ai
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s top health agency has confirmed that vaping is less harmful than smoking — but not risk-free — reshaping the country’s regulatory trajectory. As Paris withdraws a proposed vape tax and debates stricter ingredient, emissions and youth-protection rules, the ANSES report signals not prohibition, but tighter technical oversight. For manufacturers, retailers and EU policymakers, France may be previewing Europe’s next phase of nicotine governance.
Special Report
Feb.23
Kansas Lawmakers Hear SB 355 to License E-Cigarette Makers, Citing Illicit China Imports
Kansas Lawmakers Hear SB 355 to License E-Cigarette Makers, Citing Illicit China Imports
Kansas lawmakers held a Senate committee hearing on Senate Bill 355 on Jan. 27. The proposal would require e-cigarette manufacturers—potentially affecting distributors as well—to obtain a state license, expanding oversight beyond retailers.
Jan.28 by 2FIRSTS.ai
Vape sellers sue to block Texas law banning e-liquids from China and other “foreign adversaries”
Vape sellers sue to block Texas law banning e-liquids from China and other “foreign adversaries”
A group of vape distributors and retailers has sued to block enforcement of a Texas law that criminalizes selling or marketing vape products containing e-liquids made wholly or partly in China or in countries designated as “foreign adversaries” by the U.S. Commerce Secretary. The plaintiffs argue the law violates the U.S. Constitution because only Congress may regulate foreign commerce.
Feb.03 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11